Both conditions are treated effectively now with recombinant human granulocyte colony-stimulating factor (G-CSF), but this treatment requires daily or alternate day subcutaneous injections and carries the potential risk of stimulating development of myeloid leukemia. The gene discussed is CSF3; the disease is myeloid leukemia.